[tpop3d-discuss]Target Price on Callisto Pharmaceuticals Set at $3.40 by
International Investment Banking Firm
EquitiesMagazine.com
equities at murity.com
Mon, 29 May 2006 22:55:07 -0500
<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1"><body bgcolor="#999999"><br>
<table bgcolor="#ffffff" align="center" border="0" cellpadding="0" cellspacing="0" width="822">
<tr>
<td>
<table align="center" border="0" cellpadding="0" cellspacing="0" width="800">
<tr>
<td><a href='http://murity.com/080E06021D0241165F161B0111070101321E1B0106015C1017130106015C1D00150E4346464A41430E400E400E414443444B47450E08.aspx' target="_new"><img name="newheader_r1_c1" src="http://images.murity.com/img/c/callisto/0101/Callisto_Bar_01.jpg" width="800" height="87" border="0" alt=""></a></td>
<td><img src="http://www.callistopharma.com/images/spacer.gif" width="1" height="89" border="0" alt=""></td>
</tr>
<tr>
<td rowspan="2"><table width="800" border="0" cellpadding="0" cellspacing="0">
<tr>
<td><a href='http://murity.com/080E06021D0241165F161B0111070101321E1B0106015C1017130106015C1D00150E4346464A41430E400E400E414443444B47450E08.aspx' target="_new"><img src="http://images.murity.com/img/c/callisto/0101/Callisto_Bar_02.jpg" width="489" height="34" border="0"></a></td>
<td><a href='http://murity.com/080E06021D0241165F161B0111070101321E1B0106015C1017130106015C1D00150E4346464A41430E400E400E414443444B47450E08.aspx' target="_new"><img src="http://images.murity.com/img/c/callisto/0101/Callisto_Bar_03.jpg" width="65" height="34" border="0"></a></td>
<td><a href='http://murity.com/080E06021D0241165F161B0111070101321E1B0106015C1017130106015C1D00150E4346464A41430E400E400E414443444B4A420E08.aspx' target="_new"><img src="http://images.murity.com/img/c/callisto/0101/Callisto_Bar_04.jpg" width="57" height="34" border="0"></a></td>
<td><a href='http://murity.com/080E06021D0241165F161B0111070101321E1B0106015C1017130106015C1D00150E4346464A41430E400E400E414443454242410E08.aspx' target="_new"><img src="http://images.murity.com/img/c/callisto/0101/Callisto_Bar_05.jpg" width="58" height="34" border="0"></a></td>
<td width="60"><a href='http://murity.com/080E06021D0241165F161B0111070101321E1B0106015C1017130106015C1D00150E4346464A41430E400E400E414443454240440E08.aspx' target="_new"><img src="http://images.murity.com/img/c/callisto/0101/Callisto_Bar_06.jpg" width="58" height="34" border="0"></a></td>
<td width="52"><a href='http://murity.com/080E06021D0241165F161B0111070101321E1B0106015C1017130106015C1D00150E4346464A41430E400E400E41414542454A4A0E08.aspx' target="_new"><img src="http://images.murity.com/img/c/callisto/0101/Callisto_Bar_07.jpg" width="73" height="34" border="0"></a></td>
</tr>
</table></td>
<td><img src="http://www.callistopharma.com/images/spacer.gif" width="1" height="21" border="0" alt=""></td>
</tr>
<tr>
<td><img src="http://www.callistopharma.com/images/spacer.gif" width="1" height="13" border="0" alt=""></td>
</tr>
</table>
<table bgcolor="#FFFFFF" align="center" border="0" cellpadding="0" cellspacing="10" width="100%">
<tr>
<td height="1" style="FONT-SIZE: 2px;"></td>
</tr>
<tr>
<td valign="top">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tr>
<td width="160" valign="top" align="center" bgcolor="#e6e6ff"><img src="http://www.callistopharma.com/images/picture1.jpg" width="140" height="188"></td>
<td width="100%" valign="top" bgcolor="#ffffff"><table border="0" cellspacing="0" cellpadding="10">
<tr>
<td><p><font size="2"><span style="font-weight: bold;"> <font color="#003366" size="3" face="Verdana, Arial, Helvetica, sans-serif">Callisto Pharmaceuticals, Inc</font></span> <font color="#003366" size="3" face="Verdana, Arial, Helvetica, sans-serif"><span style="font-weight: bold;"> AMEX: KAL</span><br>
<br>
<strong>Target Price on Callisto Pharmaceuticals Set at $3.40 by International Investment Banking Firm</strong></font><font size="3" face="Verdana, Arial, Helvetica, sans-serif"><strong></strong></font></font></p>
<p><font color="#003366" size="2" face="Verdana, Arial, Helvetica, sans-serif">NEW YORK, May 25 /PRNewswire-FirstCall/ -- Bryan, Garnier & Co., an investment banking firm, announced today that it has initiated research coverage of Callisto Pharmaceuticals, Inc. (Amex: <a href='http://murity.com/080E06021D0241165F161B0111070101321E1B0106015C1017130106015C1D00150E4346464A41430E400E400E4143454243474B0E08.aspx' target="_new">KAL</a> - <a href='http://murity.com/080E06021D0241165F161B0111070101321E1B0106015C1017130106015C1D00150E4346464A41430E400E400E41414542454A4A0E08.aspx'>News</a>), (Frankfurt: <a href='http://murity.com/080E06021D0241165F161B0111070101321E1B0106015C1017130106015C1D00150E4346464A41430E400E400E414440404341400E08.aspx' target="_new">CA4</a> - <a href='http://murity.com/080E06021D0241165F161B0111070101321E1B0106015C1017130106015C1D00150E4346464A41430E400E400E414440404347470E08.aspx' target="_new">News</a>), a developer of new drug treatments in the fight against cancer and other major health threats. Bryan, Garnier gave Callisto a BUY rating and targets the Company's potential share price at $3.40. Bryan, Garnier & Co. is a financial planning and investment management firm serving private investors, corporations, and institutions worldwide. To view a copy of the full report, go to http://www.bryangarnier.com and click on "Research" to read more about why Bryan, Garnier & Co believe that KAL is a BUY.<br>
</font></p>
<p><font color="#003366" size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>About Callisto Pharmaceuticals, Inc.</strong></font></p>
<p><font color="#003366" size="2" face="Verdana, Arial, Helvetica, sans-serif">Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and other serious afflictions. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs for other significant health care markets, including ulcerative colitis and biodefense. One of the Company's lead drug candidates, L-Annamycin, is being developed as a treatment for forms of relapsed acute leukemia, a currently incurable blood cancer. Callisto initiated a clinical trial of L-Annamycin in adult relapsed acute lymphocytic leukemia patients in 4Q 2005. L-Annamycin, a new compound from the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including activity against resistant diseases and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives. Another anti-cancer drug, Atiprimod, is in development to treat relapsed multiple myeloma, a blood cancer, and advanced carcinoid cancer. Atiprimod is presently in Phase I/IIa human clinical trials in relapsed multiple myeloma patients, and advanced cancer patients, respectively. Callisto also has drugs in preclinical development for gastrointestinal inflammation, and a program focused on the development of a drug to protect against Staphylococcus and Streptococcus biowarfare agents. Callisto has exclusive worldwide licenses from AnorMED Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and L-Annamycin, respectively. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. For additional information, visit <a href='http://murity.com/080E06021D0241165F161B0111070101321E1B0106015C1017130106015C1D00150E4346464A41430E400E400E41404A424B42460E08.aspx' target="_new">http://www.callistopharma.com</a>.</font></p>
<p><font color="#003366" size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>Forward-Looking Statements</strong></font></p>
<p><font color="#003366" size="2" face="Verdana, Arial, Helvetica, sans-serif">Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Callisto believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the Callisto Pharmaceuticals Annual Report on Form 10-K/A for the year ended December 31, 2005, and other periodic reports, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that products that appeared promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the risk that Callisto will not obtain approval to market its products, the risks associated with dependence upon key personnel and the need for additional financing.</font></p>
<p><font color="#003366" size="2" face="Verdana, Arial, Helvetica, sans-serif">Source: Callisto Pharmaceuticals, Inc</font></p></td>
</tr>
</table></td>
</tr>
<tr>
<td bgcolor="#ffffff" colspan="4"> </td>
</tr>
<tr>
<td colspan="4" align="center" valign="top" bgcolor="#e6e6FF"> <br> <span style="font-family: Verdana, Arial, Helvetica, sans-serif;
font-size: 12px;
text-decoration: none;
color: #999999;">Please
read the <a href='http://murity.com/080E06021D0241165F161B0111070101321E1B0106015C1017130106015C1D00150E4346464A41430E400E400E414443454245400E08.aspx' target="_new" style="font-family: Verdana, Arial, Helvetica, sans-serif;
font-size: 12px;
text-decoration: none;
color: #999999;">disclaimer</a> before
continuing further. <br>
©2003 Callisto Inc.. All rights reserved
</span><br> </td>
</tr>
<tr>
<td colspan="2"><font color="#999999" face="'Trebuchet MS',Verdana,Helvetica,sans-serif" size="1" style="FONT-FAMILY: 'Trebuchet MS',Verdana,Helvetica,sans-serif;FONT-SIZE: 7pt;COLOR: #999999;"> <b>Disclaimer:</b> Some statements may contain so-called "forward-
looking statements" within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934. The Private
Securities Litigation Reform Act of 1995 provides a
safe harbor for forward-looking statements made
herein. These forward-looking statements are not
historical facts, but reflect current expectations,
estimates and projections. No assurance is given
that these estimates, expectations or projections will
be achieved. Many factors could cause actual results
to differ. Investors should consult with their
investment advisor, attorneys and other
professionals concerning any stock transaction.
Equities Magazine has relied upon information
supplied by its customers, which it believes to be
reliable; however, such reliability cannot be
guaranteed. Equities Magazine makes no
representations as to the accuracy, timeliness or
completeness of the information contained in any
such advertisement and disclaims any and all liability
relating thereto. Equities Magazine is not responsible
for any claims made by the companies advertised
herein. None of the materials or advertisements
herein constitute offers or solicitations to purchase
or sell securities of the companies profiled herein and
any decision to invest in any such company or other
financial decisions should not be made based upon
the information provided herein. Instead Equities
Magazine urges you to conduct a complete and
independent investigation of the respective
companies and consider of all pertinent risks. Equities
Magazine does not offer such advice or analysis, and
Equities Magazine further urges you to consult your
own independent tax, business, financial and
investment advisors. Equities Magazine has been paid
$9,000 by Callisto Pharmaceuticals, Inc. for distribution of this press release. </font> </td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="b2icopyrightTable">
<tr>
<td width="100%" height="37" align="center" class="b2icopyright"> </td>
</tr>
</table>
<br><br><table width='500' border='0' align='center' cellpadding='2' cellspacing='3'><tr><td align='center'> <p align='center'>
<div align='center'><a href='http://murity.com/080E06021D0241165F161B0111070101321E1B0106015C1017130106015C1D00150E4346464A41430E400E08.aspx'><img src='http://murity.com/img.gif' width='531' height='80' border='0'></a>
<br><img src='http://murity.com/080E06021D0241165F161B0111070101321E1B0106015C1017130106015C1D00150E4346464A41430E400E430E420E08.aspx'>
<font color="#999999" face="arial, verdana" size="2">Equities Magazine, LLC · 2118 Wilshire Blvd. #722 · Santa Monica, CA 90403</font></p></td></tr></table></body>
</html>